Funding for this research was provided by:
Department of Health, Australian Government (MRFF APP1152418)
Received: 27 October 2020
Accepted: 4 December 2020
First Online: 12 January 2021
Ethics approval and consent to participate
: Primary ethical approval for the Protocol and the Patient information and consent form has been provided by the Women’s and Children’s Hospital Network Human Research Ethics Committee: reference HREC/18/WCHN/36. Written informed consent will be obtained from each participant prior to her undertaking any study procedures.
: Not applicable.
: JC, PD, H-UM, CO and CW consult for Mirum Pharmaceuticals, H-UM consults for Metabogen, CW consults for GlaxoSmithKlein.